Ad5/3-E2F-Δ24-GMCSF achieved cancer cell killing efficacy comparable to the isogenic control without the E2F1 promoter and wild type Ad5, while being superior to the non-replicative Ad5/3luc1 (P < 0.05), which implies retained oncolytic potency despite quadruple genetic modification. Here, E2F1 is linked to cancer.